chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vaccination site erythema, Vaccination site pain
Clinical narrative: sore left arm at the injection site.; redness at the injection site.; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore left arm at the injection site.) and VACCINATION SITE ERYTHEMA (redness at the injection site.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 on 20-Apr-2020.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, the patient experienced VACCINATION SITE PAIN (sore left arm at the injection site.) and VACCINATION SITE ERYTHEMA (redness at the injection site.). At the time of the report, VACCINATION SITE PAIN (sore left arm at the injection site.) and VACCINATION SITE ERYTHEMA (redness at the injection site.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant products were reported. No treatment drugs were reported The patient was less than 50 years old.   This case was linked to MOD-2022-651006, MOD-2022-651007 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Adult patients received pediatric doses 6 years to 11 years doses  of the Moderna COVID 19 vaccine instead of bivalent booster doses by accident; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Adult patients received pediatric doses 6 years to 11 years doses  of the Moderna COVID 19 vaccine instead of bivalent booster doses by accident) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Adult patients received pediatric doses 6 years to 11 years doses  of the Moderna COVID 19 vaccine instead of bivalent booster doses by accident). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Adult patients received pediatric doses 6 years to 11 years doses  of the Moderna COVID 19 vaccine instead of bivalent booster doses by accident) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Adult patients received pediatric doses 6 years to 11 years doses  of the Moderna COVID 19 vaccine instead of bivalent booster doses by accident).    No concomitant drug was reported. No treatment drug was reported. This case contains information for the 1st of 4 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-651022, US-MODERNATX, INC.-MOD-2022-651023, US-MODERNATX, INC.-MOD-2022-651024 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-651022:This case pertains to Adult 2 US-MODERNATX, INC.-MOD-2022-651023:This case pertains to Adult 3 US-MODERNATX, INC.-MOD-2022-651024:This case pertains to Adult 4
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No Adverse event; received Moderna Bivalent vaccine on as their first primary series dose; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (received Moderna Bivalent vaccine on as their first primary series dose) and NO ADVERSE EVENT (No Adverse event) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Sep-2022, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 18-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (received Moderna Bivalent vaccine on as their first primary series dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (received Moderna Bivalent vaccine on as their first primary series dose) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (received Moderna Bivalent vaccine on as their first primary series dose).    Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.   Reporter did not allow further contact
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: came down with COVID; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (came down with COVID) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On 29-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jul-2022, the patient experienced COVID-19 (came down with COVID). At the time of the report, COVID-19 (came down with COVID) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. Concomitant medication details were not reported by the reporter. Treatment details was not reported by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: No adverse event; Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses; This spontaneous case was reported by an other health care professional and describes the occurrence of INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses).    No concomitant medications were reported. Patient received booster dose. No treatment medications were reported. The case consisted information for the second adult patient.
Sex: U
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: No adverse event; Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses; This spontaneous case was reported by an other health care professional and describes the occurrence of INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (Adult patients received pediatric doses -6 years to 11 years doses- of the Moderna COVID19 vaccine instead of bivalent booster doses).    No concomitant medications were reported. Patient received booster dose. No treatment medications were reported. The case consisted information for the third adult patient.
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No adverse event; Adult patients received pediatric doses 6 years to 11 years doses of the Moderna COVID19 vaccine instead of bivalent booster doses; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adult patients received pediatric doses 6 years to 11 years doses of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adult patients received pediatric doses 6 years to 11 years doses of the Moderna COVID19 vaccine instead of bivalent booster doses). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adult patients received pediatric doses 6 years to 11 years doses of the Moderna COVID19 vaccine instead of bivalent booster doses) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adult patients received pediatric doses 6 years to 11 years doses of the Moderna COVID19 vaccine instead of bivalent booster doses).    Concomitant medication information was not provided by the reporter.  It was reported that patient received pediatric dose of Moderna covid-19 vaccine instead of bivalent booster dose by accident.  Treatment information was not provided by the reporter.  The case consisted information for the fourth adult patient.; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-651017:This case pertains to Adult 4
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: CD4 lymphocytes, Inappropriate schedule of product administration, No adverse event, SARS-CoV-2 test, Viral load
Clinical narrative: No adverse event; First dose was administered on 01FEB2021 and 2nd shot on 26FEB2022; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 01FEB2021 and 2nd shot on 26FEB2022) and NO ADVERSE EVENT (No adverse event) in a 68-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     Concurrent medical conditions included Blood pressure high since 1985 and HIV infection (HIV for 20 years, took medications (could not pronounce the name)). Concomitant products included PROPRANOLOL HYDROCHLORIDE (INDERAL) for Blood pressure high.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 26-Feb-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 26-Feb-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 01FEB2021 and 2nd shot on 26FEB2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 01FEB2021 and 2nd shot on 26FEB2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, CD4 lymphocytes: Normal prior to vaccination and after vaccination.. On an unknown date, SARS-CoV-2 test: (Negative) Negative. On an unknown date, Viral load: Normal prior to vaccination and after vaccination..         The treatment medication was not reported.   This case was linked to MOD-2022-651069, MOD-2022-651070 (Patient Link).
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Local reaction
Clinical narrative: An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine; An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine; This spontaneous case was reported by a physician and describes the occurrence of LOCAL REACTION (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) and HYPERSENSITIVITY (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013L20A, 012M20A and 033F21A) for COVID-19 vaccination.     Concurrent medical conditions included Sulfonamide allergy (Medication allergy to sulfa (rash), Sulfa products but no vaccines and PEG), Hypertension (Recent change in status such as improvement or worsening: No) since 2019 and Depression (Recent change in status such as improvement or worsening: No) since 1997. Concomitant products included MODAFINIL and LAMOTRIGINE for Depression, CHLORTHALIDONE for Hypertension.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced LOCAL REACTION (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) and HYPERSENSITIVITY (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine). At the time of the report, LOCAL REACTION (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) and HYPERSENSITIVITY (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered LOCAL REACTION (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) and HYPERSENSITIVITY (An allergic reaction after having had 3 doses of the same vaccine /local and systemic reactions to each vaccine) to be related.    The patient reported a potential lot-related safety issue. The patient had a primary series (Jan-Feb 2021) with the Moderna vaccine followed by one booster in Nov 2022. Although patient had local and systemic reactions to each vaccine, patient had no hypersensitivity symptoms. Also reported it was unusual to had an allergic reaction after 3 doses of the same vaccine without any similar symptoms.   The patient never had COVID positive test or diagnosed.  No treatment information was provided.   This case was linked to MOD-2022-650999 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Immunisation reaction
Clinical narrative: unspecified side effects; This spontaneous case was reported by a patient and describes the occurrence of IMMUNISATION REACTION (unspecified side effects) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (unspecified side effects). At the time of the report, IMMUNISATION REACTION (unspecified side effects) outcome was unknown.            No Concomitant medications were provided.  It was reported that patient received the updated Moderna booster on 25 Sep 2022 and had some questions regarding side effects, but call got disconnected before agent could ask for further details.  No treatment medications were provided.   Reporter did not allow further contact
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: tested positive for Covid; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (tested positive for Covid) in a 67-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     Concurrent medical conditions included Restless legs, Parathyroid disorder NOS and Osteoporosis. Concomitant products included CALCIUM for Parathyroid disorder NOS and Osteoporosis, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE (MIRAPEX) for Restless legs.    On 25-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced COVID-19 (tested positive for Covid). At the time of the report, COVID-19 (tested positive for Covid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Sep-2022, SARS-CoV-2 test: (Positive) Positive.         On 25-Feb-2021, the patient received first dose (lot number 011A21A) of Moderna vaccine. On 29-Mar-2021, the patient received second dose (lot number 044A21A) of Moderna vaccine. On 31-Oct-2021, the patient received first booster dose (lot number 076C21A) of Moderna vaccine. On 04-Apr-2022, the patient received second booster dose (lot number 065K21A) of Moderna vaccine. He had flu vaccine on the same day he had the bivalent booster 25-Sep-2022.             No treatment information was provided by the reporter.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Administered with monovalent vaccine instead of bivalent as booster, administered with 0.5 ml of red cap vaccine as booster; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Administered with monovalent vaccine instead of bivalent as booster, administered with 0.5 ml of red cap vaccine as booster) and NO ADVERSE EVENT (No adverse event) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 057A22A, 939905 and 0038A22A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-May-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Sep-2022, received fifth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 27-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Administered with monovalent vaccine instead of bivalent as booster, administered with 0.5 ml of red cap vaccine as booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Administered with monovalent vaccine instead of bivalent as booster, administered with 0.5 ml of red cap vaccine as booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Administered with monovalent vaccine instead of bivalent as booster, administered with 0.5 ml of red cap vaccine as booster).    The concomitant medication was not reported by reporter. The treatment medication was not reported by reporter.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Influenza like illness, Myalgia, Pyrexia, Vaccination site pain
Clinical narrative: Flu like Symptoms; Dizziness; Low fever; Body Aches; Tenderness in shot area; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like Symptoms), DIZZINESS (Dizziness), PYREXIA (Low fever), MYALGIA (Body Aches) and VACCINATION SITE PAIN (Tenderness in shot area) in a 51-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7163B) for COVID-19 prophylaxis.     Patient reported no allergies and never tested COVID-19 positive.  Previously administered products included for Product used for unknown indication: Pfizer (Patient received previous dose from pfizer). Past adverse reactions to the above products included No adverse event with Pfizer. Concurrent medical conditions included Ankylosing spondylitis (Patient has ankylosing spondylitis for years, but does not take immunosuppressant medications.).    On 26-Sep-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 27-Sep-2022, the patient experienced INFLUENZA LIKE ILLNESS (Flu like Symptoms), DIZZINESS (Dizziness), PYREXIA (Low fever), MYALGIA (Body Aches) and VACCINATION SITE PAIN (Tenderness in shot area). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like Symptoms), DIZZINESS (Dizziness), PYREXIA (Low fever), MYALGIA (Body Aches) and VACCINATION SITE PAIN (Tenderness in shot area) outcome was unknown.            On 27Sep2022 in the afternoon he had low fever, body aches, dizziness, tenderness in shot area and flu like symptoms  Patient received concomitant medication but patient does not feel comfortable providing this information. No treatment information were reported by the reporter.
Age: 10.0
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No adverse event; pediatric patient receiving bivalent booster; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (pediatric patient receiving bivalent booster) and NO ADVERSE EVENT (No adverse event) in a 10-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Sep-2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 27-Sep-2022, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (pediatric patient receiving bivalent booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (pediatric patient receiving bivalent booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (pediatric patient receiving bivalent booster).    No concomitant medication information was provided. No treatment medication were provided.
Sex: M
Vaccine: COVID19
Symptoms: Ear pain
Clinical narrative: Terrible ear ache; This spontaneous case was reported by a patient family member or friend and describes the occurrence of EAR PAIN (Terrible ear ache) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 26-Sep-2022, the patient experienced EAR PAIN (Terrible ear ache). At the time of the report, EAR PAIN (Terrible ear ache) had not resolved. No concomitant medication was reported.  No treatment medication was reported. This case was linked to US-MODERNATX, INC.-MOD-2022-651165 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-651165:Wife case, same reporter
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Ear pain, Pyrexia
Clinical narrative: On 26Sep2022 patient had developed a terrible ear ache which is still ongoing today; Patient had 102°F fever, she was fine by 25Sep2022; This spontaneous case was reported by a patient and describes the occurrence of EAR PAIN (On 26Sep2022 patient had developed a terrible ear ache which is still ongoing today) and PYREXIA (Patient had 102°F fever, she was fine by 25Sep2022) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 24-Sep-2022, the patient experienced PYREXIA (Patient had 102°F fever, she was fine by 25Sep2022). On 26-Sep-2022, the patient experienced EAR PAIN (On 26Sep2022 patient had developed a terrible ear ache which is still ongoing today). On 25-Sep-2022, PYREXIA (Patient had 102°F fever, she was fine by 25Sep2022) had resolved. At the time of the report, EAR PAIN (On 26Sep2022 patient had developed a terrible ear ache which is still ongoing today) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Sep-2022, Body temperature: 102 Degree F.         It was reported that the patient earlier had taken Moderna vaccine. No concomitant medications were reported. No treatment details were reported.   This case was linked to MOD-2022-651161 (E2B Linked Report). This case was linked to MOD-2022-651168 (Patient Link).; Sender's Comments:  MOD-2022-651161:Husband's case, same reporter
Sex: M
Vaccine: COVID19
Symptoms: Illness
Clinical narrative: Got sick after 1st primary shot/Got sick after 2nd primary shot/Got sick after 1st Booster shot/Got sick  after 2nd Booster shot; This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (Got sick after 1st primary shot/Got sick after 2nd primary shot/Got sick after 1st Booster shot/Got sick  after 2nd Booster shot) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In March 2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2022, the patient experienced ILLNESS (Got sick after 1st primary shot/Got sick after 2nd primary shot/Got sick after 1st Booster shot/Got sick  after 2nd Booster shot). At the time of the report, ILLNESS (Got sick after 1st primary shot/Got sick after 2nd primary shot/Got sick after 1st Booster shot/Got sick  after 2nd Booster shot) outcome was unknown.            Concomitant medication information was not provided by the reporter.  He stated that he received 4 doses of Monovalent Moderna COVID-19 vaccine already.  Treatment information was not provided by the reporter.   Reporter did not allow further contact
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Chromaturia
Clinical narrative: urine was bright orange; This spontaneous case was reported by a pharmacist and describes the occurrence of CHROMATURIA (urine was bright orange) in a 30-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. as7163b) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer COVID19 vaccine (1st booster) on 09-Mar-2021, COVID-19 vaccine (1st dose.) and COVID-19 vaccine (2nd dose.). Past adverse reactions to the above products included No adverse event with COVID-19 vaccine, COVID-19 vaccine and Pfizer COVID19 vaccine.    On 27-Sep-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHROMATURIA (urine was bright orange). At the time of the report, CHROMATURIA (urine was bright orange) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pyrexia
Clinical narrative: experiencing fatigue; mild headache; slight fever no more than 100°F during 48 hours; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (experiencing fatigue), HEADACHE (mild headache) and PYREXIA (slight fever no more than 100°F during 48 hours) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027L21A, 011F21A and 014M20A) for COVID-19 vaccination.     Patient did not have any allergies related to medications, food and other products. Patient never tested positive or diagnosed with COVID.  Concurrent medical conditions included Enlarged prostate (Condition was worsening.) since 1990, Blood pressure high and High cholesterol. Concomitant products included WARFARIN, ATORVASTATIN and HYDROCHLOROTHIAZIDE, LISINOPRIL (ZESTORETIC) for an unknown indication.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FATIGUE (experiencing fatigue) and HEADACHE (mild headache). an unknown date, the patient experienced PYREXIA (slight fever no more than 100°F during 48 hours). At the time of the report, FATIGUE (experiencing fatigue), HEADACHE (mild headache) and PYREXIA (slight fever no more than 100°F during 48 hours) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pyrexia: no more than 100°F.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient had current condition of prosthetic mitral valve (no change in condition).  No treatment medications was reported.   This case was linked to MOD-2022-651167, MOD-2022-651186 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Underdose
Clinical narrative: patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose; No Adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose) and NO ADVERSE EVENT (No Adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose) and NO ADVERSE EVENT (No Adverse event). At the time of the report, UNDERDOSE (patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose).    No concomitant medication was reported. It was reported that a patient may have potentially only received 0.25ml of the Moderna Covid-19 bivalent vaccine dose. INo other events are known of. No treatment medication was reported.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: had sore arm; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (had sore arm) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (had sore arm). At the time of the report, PAIN IN EXTREMITY (had sore arm) outcome was unknown.            Concomitant medication was not reported. It was reported that patient had sore arm with the previous doses of Moderna vaccine and nothing else. Treatment medications was not reported.   Reporter did not allow further contact
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: No adverse event, Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8° (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded to Agency on 06-JUL-2022 from a consumer.   The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.   FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded to Agency on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003724, MCM-003726, MCM-003729, MCM-003734, MCM-003735, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: No adverse event, Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8° (10 mins); This non-serious spontaneous report was received by partner (reference number 02197725) on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003724, MCM-003729, MCM-003734, MCM-003735, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: U
Vaccine: DTPPVHBHPB
Symptoms: Product storage error
Clinical narrative: Caller reports multiple doses of VAXELIS administered since temperature excursion; This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded to agency on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.
Sex: U
Vaccine: DTPPVHBHPB
Symptoms: Product storage error
Clinical narrative: Caller reports multiple doses of VAXELIS administered since temperature excursion; This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: No adverse event, Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8° (10 mins); This non-serious spontaneous report was received by partner (reference: 02197725) on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.   FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003724, MCM-003734, MCM-003735, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8° (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003724, MCM-003724, MCM-003735, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: No adverse event, Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003729, MCM-003734, MCM-003724, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003729, MCM-003734, MCM-003735, MCM-003724, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
Sex: M
Vaccine: DTPPVHBHPB
Symptoms: No adverse event, Product storage error
Clinical narrative: VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003729, MCM-003734, MCM-003735, MCM-003737, MCM-003724, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003763, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.